Divi's Laboratories · NSE: DIVISLAB · BSE: 532488
Q3 FY22 results · Oct–Dec 2021
Divi's Laboratories reported revenue from operations of ₹2,493.24 crore (up 46.5% from Q3 FY21) and net profit of ₹902.24 crore (up 91.7% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,493.24 | 1,701.44 | +46.5% | 1,987.51 | +25.4% |
| Other income | 16.62 | 19.32 | −14.0% | 19.11 | −13.0% |
| Total income | 2,509.86 | 1,720.76 | +45.9% | 2,006.62 | +25.1% |
| Profit before tax | 1,033.66 | 642.08 | +61.0% | 759.62 | +36.1% |
| Net profit for the period | 902.24 | 470.62 | +91.7% | 606.46 | +48.8% |
| Attributable to shareholders of the company | 902.92 | 470.62 | +91.9% | 606.64 | +48.8% |
| EPS, basic (₹) | 33.99 | 17.73 | +91.7% | 22.84 | +48.8% |
| Net margin (%) | 36.2 | 27.7 | 30.5 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,466.77 | 1,656.48 | +48.9% | 1,967.86 | +25.4% |
| Other income | 16.62 | 19.68 | −15.5% | 19.11 | −13.0% |
| Total income | 2,483.39 | 1,676.16 | +48.2% | 1,986.97 | +25.0% |
| Profit before tax | 1,036.62 | 629.96 | +64.6% | 760.44 | +36.3% |
| Net profit for the period | 907.22 | 461.24 | +96.7% | 606.39 | +49.6% |
| EPS, basic (₹) | 34.17 | 17.37 | +96.7% | 22.84 | +49.6% |
| Net margin (%) | 36.8 | 27.8 | 30.8 |
Consolidated
- Filed with BSE
- 11 Feb 2022, 17:01 IST
- Board meeting
- 11 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Feb 2022, 17:01 IST
- Board meeting
- 11 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE